Welcome to Traders News Source,
Stay tuned and keep an eye on your inbox for our next hot small-Mid Cap stock report coming soon.
Do not forget to add us to your preferred/safe senders list within your email service provider.
Click the icon below to join our text alerts and receive our reports in real time, its quick, easy and free.
NOTICE THIS REPORT CONTAINS ERRORS IN REGARDS TO THE INVOLVEMENT OF CHICAGO VENTURES. WE HAVE BEEN NOTIFIED BY LINDSAY KNIGHT AT CHICAGO VENTURES THAT THE PUBLIC INFORMATION WE RELIED ON IS INACCURATE. THE QUOTE HAS BEEN REMOVED.
Progressive Care, Inc. (OTCQB: RXMD), through its subsidiaries Smart Medical Alliance, Inc. and PharmCo, LLC, is a South Florida health services organization and provider of prescription pharmaceuticals.
RXMD shares began 2018 at a price of $.014 and have a current price of $.18, a nearly 1300% increase.
The Company recently signed a letter of intent to purchase a pharmacy in Palm Beach County for $300,000.
The company announced over $20 million in net revenues for 2017, an 11% increase over 2016, and it filled approximately 225,000 prescriptions in 2017.
Recent Events
On March 2, 2018. The Company signed a letter of intent to purchase a pharmacy in Palm Beach County for $300,000. The Company is beginning the due diligence process with anticipated closing to occur in the second quarter of 2018. The acquisition target is located close to major highways in a 3,000 sq. ft facility. The operation has experienced staff, all applicable licenses, commensurate PBM contracts as PharmCo, LLC, and a Parata PASS 500-unit dose packaging system. https://finance.yahoo.com/news/progressive-care-executes-letter-intent-132212747.html
March 1, 2018. Progressive Care announced that 23,000 prescriptions were filled during the month of January, generating $1.8 million in net revenues. That is record for the Company and up 34% from the same month in 2017. RXMD is also proud of the work they are accomplishing with Mass Ventures Corp, a Florida company, who has significantly enhanced the digital presence and technology solutions for the company and all subsidiaries. Other important achievements include the expansion into Palm Beach County and the news that its retail pharmacy will officially begin accepting Bitcoin payments. https://finance.yahoo.com/news/parikh-mars-ceo-progressive-care-130000979.html
January 25, 2018. Progressive Care engages Mass Ventures Corp to initiate a digital marketing campaign for both Progressive Care and PharmCo, LLC. The principle of Mass Ventures will be located on-site to provide real-time updates as needed. The campaign consists of many features including, but not limited to, website upgrades, enhanced and updated content, blog posting, social media development, press release distribution, search engine optimization, etc. https://finance.yahoo.com/news/progressive-care-engages-mass-ventures-132318670.html
About
Progressive Care Inc. (RXMD), through its subsidiaries Smart Medical Alliance, Inc. and PharmCo, LLC, is a South Florida health services organization and provider of prescription pharmaceuticals, compounded medications, provider of tele-pharmacy services, the sale of anti-retroviral medications, medication therapy management (MTM), the supply of prescription medications to long term care facilities, administration and practice management, utilization management, quality assurance, EHR Implementation, billing and coding, and health practice risk management.
Company Outlook
2017 Key Highlights
Change of listing tier to OTCQB
Addition of Independent Board Members: Jervis Hough and Oleg Firer
Majority Independent Audit Committee
Completion of 2016 Audited Financial Statements
225,000 prescriptions filled
Over 21,000 prescriptions filled in a single month
Over $20 million in net revenues
Secured Community AIDS Network 340B contract.
Doubled monthly 340B revenues since December 2016
Raised over $2.75 million for 340B charitable organizations
Reached over 50 employees
Developed a tele-pharmacy platform in conjunction with software provider MDFlow
Licensed in the following states: Colorado, Connecticut, Florida, Georgia, Illinois, Nevada, New Jersey, New York, Pennsylvania, Texas, Utah, Arizona, Massachusetts
5-star rating
Opened first PharmCo Pharmacy Resource Center
Celebrated PharmCo’s 10-year anniversary
Strategic goals for 2018:
Achieve 25,000 prescriptions filled in a single month by December 2018
Increase annual overall sales to $22 million
Secure additional 340B contracts and long-term care facility relationships
Further expansion into Palm Beach County
Achieve accreditation for non-sterile compounding
Achieve full enterprise profitability and earnings growth
Publish 2nd year of audited financial statements and leverage these statements to secure new investment opportunities for mergers and acquisitions
Opening more Pharmco Pharmacy Resource Centers in retirement and long-term care communities.
Strengthening our tele-pharmacy platform
Financial Review, Q3 and 9 Months Ending September 30, 2017
For the three months ended September 30, 2017, the Company increased overall revenue to approximately $5.1 million, which resulted from 5% organic revenue growth over the same period in 2016. Gross profit margins decreased from 28% in 2016 to 23% in 2017, a 14% decrease when compared to the same period in 2016. Operating income decreased by approximately $90,000 in 2017 as compared to 2016.
For the nine months ended September 30, 2017, the Company increased overall revenue to approximately $15.1 million, a 14% increase over the same period in 2016. Gross profit margins increased from 26% in 2016 to 27% in 2017, a 16% increase when compared to 2016. Operating income decreased by approximately $254,000 in 2017 as compared to 2016.
Operating expenses increased $802,223 or 25% for the nine months ended September 30, 2017 as compared to the nine months ended September 30, 2016. Operating Expenses as a percent of sales increased to 27%, a 25% increase as compared to the same period in 2016.
Stock Influences and Risk Factors
Continuing increases in revenue could be a catalyst for RXMD shares;
The closing of the current pharmacy acquisition may be a positive for the company;
The company may need to raise cash beyond its credit facilities and could implement dilutive solutions;
Efforts to reduce reimbursement levels and alter health care financing practices could adversely affect the businesses;
The industries in which RXMD operates are extremely competitive and competition could adversely affect their business.
Stock Chart
Disclaimer
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Traders News Source has not been compensated for this report by anyone and the opinions if any are that of the author Vikas Agrawal, CFA. Author’s Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I, wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in the article.
This web site, published by TNS LLC, and is an investment newsletter that is built on the premise of assisting individual investors in learning about investing. Our goal as publishers of financial information is to provide research and analysis of investments to our subscribers. TNS LLC does not give buy or sell recommendations. We do purchase distribution rights from analyst, financial writers and bloggers for a fee that may be licensed to issue price targets and recommendations. Furthermore, we encourage you to speak to a licensed professional prior to making an investment in any type of publicly traded security.
We do sell advertising to other companies including brokerage firms, web sites, publicly traded issuers, investor relations firms, and investment publications, among others. TNS LLC makes no warranty as to the policies of these organizations, and in no way endorses their offers, services, or the content of their advertisements.
When an advertiser is a publicly traded company or a third party acting on behalf of a public company, we fully disclose all compensation in the email advertisement. Such disclosure is included in a disclosure statement in each of the advertisements sent via email.
17B Disclosure
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operator’s owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.
TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur.
Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
